Primary cutaneous lymphomas: a review with current treatment options.
Primary cutaneous T- and B-cell lymphomas are a heterogenous group of diseases with varied clinical presentations and prognosis. The use of new molecular, histological, and clinical criteria have enhanced the recognition of primary cutaneous T- and B-cell lymphomas. Compared to their nodal counterpart they have a different clinical behavior and therefore require a different treatment approach. Independent predictive factors identified clinically, histologically, and by immunopheno- and immunogenotyping are essential to assess the appropriate treatment for each subtype. The European Organization for Research and Treatment of Cancer (EORTC) Cutaneous Lymphoma Study Group provide a classification of cutaneous lymphomas taking into account of the histological and molecular features. Based on this classification we will provide a summary of the current medical literature in diagnosis, treatment, and prognosis for primary cutaneous lymphomas with emphasis on new treatment strategies.
Querfeld
Christiane
C
Department of Dermatology, Feinberg School of Medicine, Northwestern University, Chicago, Illinois, USA.
Guitart
Joan
J
Kuzel
Timothy M
TM
Rosen
Steven T
ST
D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D016207:Cytokines / Q000627:therapeutic use; D005060:Europe; D006801:Humans; D000922:Immunotoxins / Q000627:therapeutic use; D016393:Lymphoma, B-Cell / Q000145:classification / Q000188:drug therapy / Q000473:pathology*; D016410:Lymphoma, T-Cell, Cutaneous / Q000145:classification / Q000188:drug therapy / Q000473:pathology*; D008297:Male; D009182:Mycosis Fungoides / Q000188:drug therapy / Q000473:pathology; D012176:Retinoids / Q000627:therapeutic use; D012751:Sezary Syndrome / Q000188:drug therapy / Q000473:pathology; D012878:Skin Neoplasms / Q000145:classification / Q000188:drug therapy / Q000473:pathology*; D014944:World Health Organization
D000911:Antibodies, Monoclonal; D016207:Cytokines; D000922:Immunotoxins; D012176:Retinoids